Decreased STAT3 in human idiopathic fetal growth restriction contributes to trophoblast dysfunction

A J Borg1, H E J Yong1, M Lappas2

  • 1Department of Perinatal MedicinePregnancy Research Centre, The Royal Women's Hospital, Parkville, Victoria, AustraliaDepartment of Obstetrics and GynaecologyUniversity of Melbourne, Melbourne, Victoria, AustraliaDepartment of Obstetrics and GynaecologyMercy Hospital for Women, Heidelberg, Victoria, AustraliaINSERM-U767Faculté des Sciences Pharmaceutiques et Biologiques, Paris F-75006, FranceUniversite Paris DescartesParis F-75006, FrancePremUp FoundationParis F-75006, FranceCollege of Science and Health ProfessionsKing Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi ArabiaSchool of Women's and Infants' HealthKing Edward Memorial Hospital, University of Western Australia, Subiaco, Western Australia, Australia Department of Perinatal MedicinePregnancy Research Centre, The Royal Women's Hospital, Parkville, Victoria, AustraliaDepartment of Obstetrics and GynaecologyUniversity of Melbourne, Melbourne, Victoria, AustraliaDepartment of Obstetrics and GynaecologyMercy Hospital for Women, Heidelberg, Victoria, AustraliaINSERM-U767Faculté des Sciences Pharmaceutiques et Biologiques, Paris F-75006, FranceUniversite Paris DescartesParis F-75006, FrancePremUp FoundationParis F-75006, FranceCollege of Science and Health ProfessionsKing Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi ArabiaSchool of Women's and Infants' HealthKing Edward Memorial Hospital, University of Western Australia, Subiaco, Western Australia, Australia.

Reproduction (Cambridge, England)
|February 26, 2015
PubMed

Insights

Decreased STAT3 expression in placentas is linked to abnormal trophoblast function in fetal growth restriction (FGR). This finding suggests STAT3 plays a crucial role in feto-placental development and may be a target for FGR interventions.

Area of Science:

  • Reproductive Biology
  • Molecular Genetics
  • Cellular Signaling

Background:

  • Abnormal trophoblast function is a known contributor to fetal growth restriction (FGR).
  • The Janus kinase-STAT (JAK-STAT) signaling pathway regulates critical cellular processes including proliferation, differentiation, migration, and apoptosis.
  • The role of JAK-STAT pathway gene expression in human idiopathic FGR remains largely unexplored.

Purpose of the Study:

  • To investigate the hypothesis that JAK-STAT pathway genes are differentially expressed in idiopathic FGR pregnancies.
  • To determine if altered JAK-STAT gene expression contributes to abnormal feto-placental growth.
  • To examine the modulation of SNAT2, CGB/β-hCG, caspase 3/8, and TP53 expression by JAK-STAT in FGR.

Main Methods:

  • Expression profiling of placental JAK-STAT genes in FGR and control pregnancies.
  • Validation of gene expression using real-time PCR and immunoblotting.
  • In vitro modeling of syncytiotrophoblast differentiation using primary trophoblast cells and BeWo cells, with STAT3 knockdown via siRNA.

Main Results:

  • mRNA levels of STAT3, STAT2, and STAT5B were significantly decreased in FGR placentae compared to controls.
  • Lower STAT3 mRNA and protein (total and phosphorylated) levels were confirmed in FGR placentae.
  • STAT3 knockdown in BeWo cells led to increased CGB/β-hCG, caspase 3/8, and TP53 expression, and decreased SNAT2 expression.

Conclusions:

  • Decreased STAT3 expression in the placenta is associated with abnormal trophoblast function in idiopathic FGR.
  • STAT3 may play a critical role in regulating trophoblast differentiation and function relevant to feto-placental growth.
  • Altered STAT3 signaling could be a contributing factor to the pathophysiology of FGR.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.1K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K